AKT1 and posterior cortical atrophy: Dactolisib is a dual PI3K and mTORC1/2 inhibitor that inhibits p-AKT up-regulation through mTORC2 and so is expected to show antitumor activity against various human cancers including PCa than mTORC1 inhibitors.